These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6597236)

  • 41. [Cytosine arabinoside in the treatment of acute childhood leukemia: clinical contribution].
    Masera G; Carnelli V; Uderzo C
    Haematologica; 1972; 57(7):397-409. PubMed ID: 4628586
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapy of acute leukemia. 4. Remission induction and remission maintenance therapy].
    Hirano M; Uetani T; Morita A; Sako F; Koie K
    Saishin Igaku; 1971 Oct; 26(10):2034-41. PubMed ID: 5288692
    [No Abstract]   [Full Text] [Related]  

  • 43. [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].
    Marthé G; Misset JL; de Vassal F; Hayat M; Gouveia J; Machover D; Belpomme D; Schwarzenberg L; Ribaud P; Pico JL; Musset M; Jasmin C; de Luca L
    Nouv Presse Med; 1978 Feb; 7(7):525-8. PubMed ID: 273888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [High-dose cytosine arabinoside administration in the treatment of refractory leukemia].
    Yoshida M; Furukawa Y; Akashi M; Komatsu N; Takeda K; Muroi K; Ikeda K; Ohsaka A; Ohta M; Suda K
    Rinsho Ketsueki; 1985 Aug; 26(8):1258-64. PubMed ID: 3865002
    [No Abstract]   [Full Text] [Related]  

  • 45. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
    Willemze R; Fibbe WE; Zwaan FE
    Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
    [No Abstract]   [Full Text] [Related]  

  • 46. High-dose cytosine arabinoside in the treatment of childhood malignancies.
    Lie SO; Slørdahl S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):160-5. PubMed ID: 3859931
    [No Abstract]   [Full Text] [Related]  

  • 47. [Phase II study of THP-adriamycin in acute leukemia].
    Tani Y; Hirayama F; Ogawa K; Mashimoto K; Kubota R; Kanekura J; Oguma S; Veta T; Nakamura H; Shibata M
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2573-4. PubMed ID: 6580842
    [No Abstract]   [Full Text] [Related]  

  • 48. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Results of cytarabine and 6-thioguanine combination chemotherapy in acute leukemia].
    Drings P; Fritsch H; von Kaick G; Moskwa G; Sefrin R
    Verh Dtsch Ges Inn Med; 1973; 79():353-5. PubMed ID: 4524456
    [No Abstract]   [Full Text] [Related]  

  • 50. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Our recent therapeutic experiences in acute leukemia].
    Quattrin N; Montuori R; Di Girolamo R; Cimino R
    Minerva Med; 1975 Jul; 66(51):2538-45. PubMed ID: 1057050
    [No Abstract]   [Full Text] [Related]  

  • 52. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma.
    Arimori S; Nagao T; Shimizu Y; Watanabe K; Komatsuda M
    Tokai J Exp Clin Med; 1980 Jan; 5(1):63-71. PubMed ID: 6930119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of amsacrine gluconate in refractory leukemia.
    Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
    Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
    [No Abstract]   [Full Text] [Related]  

  • 55. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Cancer; 1985 Oct; 56(8):1913-7. PubMed ID: 3861233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Central nervous system toxicity with high-dose cytosine arabinoside.
    Herzig RH; Lazarus HM; Herzig GP; Coccia PF; Wolff SN
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):233-6. PubMed ID: 3892703
    [No Abstract]   [Full Text] [Related]  

  • 58. Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.
    Cho SG; Moon H; Lee JH; Lee SY; Kim CC; Lee KS
    J Korean Med Sci; 1999 Feb; 14(1):89-92. PubMed ID: 10102531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous infusion of high-dose cytosine arabinoside for treatment of childhood acute leukemia and non-Hodgkin's lymphoma in relapse.
    Jones GR; Ettinger LJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):150-4. PubMed ID: 3874431
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of refractory acute leukaemia with high dose cytosine arabinoside.
    Willemze R; Zwaan FE; Keuning JJ; Colpin G
    Br J Haematol; 1982 Jul; 51(3):497-8. PubMed ID: 6954973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.